These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36817149)

  • 1. Impact of polymorphisms in
    Calleja S; Zubiaur P; Ochoa D; Villapalos-García G; Mejia-Abril G; Soria-Chacartegui P; Navares-Gómez M; de Miguel A; Román M; Martín-Vílchez S; Abad-Santos F
    Front Pharmacol; 2023; 14():1110460. PubMed ID: 36817149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran.
    Zubiaur P; Saiz-Rodríguez M; Ochoa D; Navares-Gómez M; Mejía G; Román M; Koller D; Soria-Chacartegui P; Almenara S; Abad-Santos F
    Adv Ther; 2020 Aug; 37(8):3537-3550. PubMed ID: 32564268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism.
    Mejía-Abril G; Zubiaur P; Navares-Gómez M; Villapalos-García G; Román M; Ochoa D; Abad-Santos F
    Front Pharmacol; 2021; 12():660639. PubMed ID: 33995083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphism of Drug Transporters, Rather Than Metabolizing Enzymes, Conditions the Pharmacokinetics of Rasagiline.
    Zubiaur P; Matas M; Martín-Vílchez S; Soria-Chacartegui P; Villapalos-García G; Figueiredo-Tor L; Calleja S; Navares-Gómez M; de Miguel A; Novalbos J; Mejía-Abril G; Luquero-Bueno S; Román M; Ochoa D; Abad-Santos F
    Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of venlafaxine extended release 75  mg and desvenlafaxine 50  mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
    Nichols AI; Focht K; Jiang Q; Preskorn SH; Kane CP
    Clin Drug Investig; 2011; 31(3):155-67. PubMed ID: 21288052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between CYP2C19 and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam.
    Zubiaur P; Figueiredo-Tor L; Villapalos-García G; Soria-Chacartegui P; Navares-Gómez M; Novalbos J; Matas M; Calleja S; Mejía-Abril G; Román M; Ochoa D; Abad-Santos F
    Biomed Pharmacother; 2022 Nov; 155():113747. PubMed ID: 36162369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin and Norepinephrine Reuptake Inhibitors.
    Shelton RC
    Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variants in
    Zubiaur P; Fernández-Campos P; Navares-Gómez M; Soria-Chacartegui P; Villapalos-García G; Román M; Mejía-Abril G; Ochoa D; Abad-Santos F
    Pharmaceutics; 2021 Sep; 13(10):. PubMed ID: 34683865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SLCO1B1 and ABCG2 genotype-informed phenotypes are related to variation in ramipril exposure.
    Abbes H; Zubiaur P; Soria-Chacartegui P; de la Torre T; Villapalos-García G; Candau C; Rodríguez-Lopez A; González-Iglesias E; Aldama M; Navares-Gomez M; Omezzine A; Ochoa D; Abad-Santos F
    Basic Clin Pharmacol Toxicol; 2024 Jul; ():. PubMed ID: 39011815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
    Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
    J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers.
    Saiz-Rodríguez M; Belmonte C; Román M; Ochoa D; Koller D; Talegón M; Ovejero-Benito MC; López-Rodríguez R; Cabaleiro T; Abad-Santos F
    Basic Clin Pharmacol Toxicol; 2018 May; 122(5):501-511. PubMed ID: 29136336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects.
    Pena MÁ; Muriel J; Saiz-Rodríguez M; Borobia AM; Abad-Santos F; Frías J; Peiró AM
    Clin Drug Investig; 2020 Jul; 40(7):617-628. PubMed ID: 32415468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities.
    Oganesian A; Shilling AD; Young-Sciame R; Tran J; Watanyar A; Azam F; Kao J; Leung L
    Psychopharmacol Bull; 2009; 42(2):47-63. PubMed ID: 19629022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers.
    Zubiaur P; Soria-Chacartegui P; Koller D; Navares-Gómez M; Ochoa D; Almenara S; Saiz-Rodríguez M; Mejía-Abril G; Villapalos-García G; Román M; Martín-Vílchez S; Abad-Santos F
    Biomed Pharmacother; 2021 Jan; 133():111087. PubMed ID: 33378980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
    Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
    J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability.
    Zubiaur P; Benedicto MD; Villapalos-García G; Navares-Gómez M; Mejía-Abril G; Román M; Martín-Vílchez S; Ochoa D; Abad-Santos F
    J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33805706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.
    Choi HY; Bae KS; Cho SH; Ghim JL; Choe S; Jung JA; Jin SJ; Kim HS; Lim HS
    Pharmacogenet Genomics; 2015 Dec; 25(12):595-608. PubMed ID: 26367500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
    Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
    Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.
    Stingl JC; Bartels H; Viviani R; Lehmann ML; Brockmöller J
    Pharmacol Ther; 2014 Jan; 141(1):92-116. PubMed ID: 24076267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
    Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
    Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.